La Dra. Martina Amiguet Comins comenta los resultados del estudio publicado en ESC Congress 2022.

1. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
FIDELITY
Presentación del ESC Congress 2022
FIDELITY
Prespecified pooled analysis from
FIDELIO-DKD+FIGARO DKD
Causes of mortality
https://doi.org/10.1093/eurheartj/ehab777

2. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Background FIDELITY: Study design Study population Results Conclusions
Presentación del ESC Congress 2022
European Heart Journal (2022) 43, 474–484
https://doi.org/10.1093/eurheartj/ehab777
FIDELITY:
The emerging risk factors collaboration. JAMA 2015.

3. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Background FIDELITY: Study design Study population Results Conclusions
Presentación del ESC Congress 2022
European Heart Journal (2022) 43, 474–484
https://doi.org/10.1093/eurheartj/ehab777
FIDELITY:
CREDENCE
Canagliflozin vs placebo in T2D with CKD
DAPA-CKD
Dapagliflozin vs placebo in CKD

4. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Background FIDELITY: Study design Study population Results Conclusions
Presentación del ESC Congress 2022
European Heart Journal (2022) 43, 474–484
https://doi.org/10.1093/eurheartj/ehab777
FIDELITY:
MR overactivation is a common pathophysiological
mechanism in cardiorenal diseases
MRA have shown a reduction on mortality in HF patients
However the effect con CKD and T2D patients is unknown
Finerenone is a distinct nonsteroideal
MRA that selectively blocks MR
overactivation.

5. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Background FIDELITY: Study design Study population Results Conclusions
Presentación del ESC Congress 2022
European Heart Journal (2022) 43, 474–484
https://doi.org/10.1093/eurheartj/ehab777
FIDELITY:

6. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Background FIDELITY: Study design Study population Results Conclusions
Presentación del ESC Congress 2022
European Heart Journal (2022) 43, 474–484
https://doi.org/10.1093/eurheartj/ehab777
FIDELITY:
https://doi.org/10.1016/j.ahjo.2022.100187

7. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Background FIDELITY: Study design Study population Results Conclusions
Presentación del ESC Congress 2022
European Heart Journal (2022) 43, 474–484
https://doi.org/10.1093/eurheartj/ehab777
FIDELITY:

8. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Background FIDELITY: Study design Study population Results Conclusions
Presentación del ESC Congress 2022
European Heart Journal (2022) 43, 474–484
https://doi.org/10.1093/eurheartj/ehab777
FIDELITY:
FINERENONE reduced cardiovascular mortality on the on-treatment analysis, compared to placebo
18%

9. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Background FIDELITY: Study design Study population Results Conclusions
Presentación del ESC Congress 2022
European Heart Journal (2022) 43, 474–484
https://doi.org/10.1093/eurheartj/ehab777
FIDELITY:

10. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Background FIDELITY: Study design Study population Results Conclusions
Presentación del ESC Congress 2022
European Heart Journal (2022) 43, 474–484
https://doi.org/10.1093/eurheartj/ehab777
FIDELITY:
The effect of finerenone on mortality seems to be greater in patients with higher baseline eGFR

11. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Background FIDELITY: Study design Study population Results Conclusions
Presentación del ESC Congress 2022
European Heart Journal (2022) 43, 474–484
https://doi.org/10.1093/eurheartj/ehab777
FIDELITY:
FINERENONE reduced cardiovascular mortality on the on-treatment analysis, compared to placebo
The most common cause of mortality was related to cardiovascular events
FINERENONE seems to have greater impact on mortality (all-cause, CV mortality and SCD) in patients with
higher baseline eGFR
THE SOONER, THE BETTER